ABSTRACT
Introduction
Spleen tyrosine kinase (SYK) is a member of the Syk family of nonreceptor cytoplasmic tyrosine kinases (Riccaboni et al., 2010) , primarily expressed in hematopoietic tissues but also in a variety of different tissues (Yanagi et al., 2001) . SYK propagates signal transduction for a number of immunoreceptor tyrosine-based activation motif-dependent proinflammatory pathways, including Fc receptor, B-cell receptor (BCR), and integrin signaling (Riccaboni et al., 2010) . The proximal location of SYK in these multiple pathways confers a broad range of anti-inflammatory activity and makes SYK an attractive therapeutic target for a range of inflammatory diseases. For example, the early and late allergic responses observed in asthma and other atopic diseases can be directly linked to the degranulation of mast cells that have been sensitized with allergen-specific IgE binding to the highaffinity IgE receptor (Fc«R1) (Allan et al., 2012) . SYK is immediately downstream of Fc«R1, and inhibition of SYK has been shown to abrogate these responses (Wex et al., 2011) . B-cell activity has been linked to other inflammatory diseases, such as rheumatoid arthritis, where they may present antigen to T cells or secrete proinflammatory cytokines and rheumatoid factor (Panayi, 2005) , and in which the B-cell-depleting antibody rituximab has been shown to be clinically effective (Cohen et al., 2006) . SYK is also downstream of BCR, and inhibition of SYK has been shown to inhibit BCR-mediated activation of B cells (Braselmann et al., 2006) . Because of this broad mechanism of action, several SYK inhibitors are currently in clinical development but all seem to be hampered by some liabilities. 4, pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido [3,2-b] [1,4]oxazin-3-one); Rigel Pharmaceuticals, South San Francisco, CA) has been evaluated in clinical trials for rheumatoid arthritis in codevelopment with AstraZeneca; however, fostamatinib failed in one of the two coprimary phase III efficacy endpoints Weinblatt et al., 2014) and is currently in development for immune thrombocytopenia and IgA-mediated nephropathy. Recent analysis suggests that the soluble prodrug of R406, R788 ([6-[[5-fluoro-2-(3,4,5-trimethoxyanilino) (Braselmann et al., 2006) , has a K d within 10-fold of the K d for SYK for 110 of 440 kinases (including FMS-related tyrosine kinase 3, lymphocyte cellspecific protein tyrosine kinase, Janus kinases JAK1 and JAK3, and c-kit), suggesting that more than 20% of the kinome may be inhibited by R406 within 10-fold of the concentration required for SYK inhibition and may thus challenge its selectivity (Davis et al., 2011) .
The dual SYK/JAK inhibitor cerdulatinib (PRT062070 [4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino] pyrimidine-5-carboxamide]; Portola Pharmaceuticals, South San Francisco, CA) is in a phase II trial for leukemia and lymphoma but also inhibits 19 other tested kinases, with IC 50 values less than 200 nM and within 100-fold of the SYK IC 50 (Coffey et al., 2014) . The more selective SYK inhibitor from Portola, PRT062607 (2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide), has also been evaluated in a phase I trial, but no further development has since been reported (Coffey et al., 2012) . Despite the increased selectivity over PRT062070, PRT062607 inhibits FGR and MLK1 within 100-fold of the SYK IC 50 (Coffey et al., 2012) . Recently, investigators started phase II trials of entospletinib amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide); Gilead Sciences, Foster City, CA] for refractory hematologic conditions and refractory lymphoma. Only nonreceptor tyrosine-protein kinase 1 was inhibited within 10-fold of the SYK IC 50 (Currie et al., 2014) ; however, 34 kinases were reported to be inhibited within 100-fold of the SYK IC 50 . Bayer published the description of an ATP-competitive selective SYK inhibitor, BAY 61-3606 (2-[7-(3,4- 
, with an IC 50 value of 10 nM on human basophils (Yamamoto et al., 2003) . However, the poor rodent pharmacokinetics (PK) profile required very high doses to achieve an inhibitory effect in vivo (Yamamoto et al., 2003; Bhagwat, 2009 ). More recently, Merck published a very potent advancement on the more selective Portola compound structure (SYK kinase IC 50 5 60 pM, whole blood basophil IC 50 5 58 nM) with which only zeta chain-associated protein kinase 70 in the 265-kinase panel was inhibited within 100-fold of the SYK IC 50 (Ellis et al., 2015) .
For respiratory diseases, the SYK inhibitor R343 (5,7-dibromoquinolin-8-ol) from Rigel Pharmaceuticals has been evaluated using the inhalation route in clinical trials in codevelopment with Pfizer, showing complete inhibition of both the early and late atopic phases after allergen challenge in individuals with mild asthma (Allan et al., 2012) . However, in a small 42-kinase panel, 12 kinases (29% of the kinase panel) were inhibited with a higher potency than SYK and 13 additional kinases (32% of the kinase panel) within 20% of SYK activity (Ramis et al., 2015) , again suggesting that a large proportion of the kinome may be inhibited. Recently, Almirall reported that another inhaled SYK inhibitor (LAS189386, 1-{2-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]pyridin-4-yl}-N-pyrazin-2-yl-1H-indazol-3-amine) shows preclinical activity in rodent models of ovalbumin (OVA)-induced early asthmatic response (Ramis et al., 2015) , although this compound exhibits only limited selectivity for SYK, with 7 other kinases (17% of the kinase panel) being inhibited within 20% of SYK activity in a short 42-kinase selectivity panel.
We report here a novel potent and selective SYK inhibitor, 
Materials and Methods
Animals. Adult, test-naïve, male brown Norway rats (48 BN/Crl, aged 15 to 16 weeks, weighing 190-250 g) were purchased from Charles River Laboratories (Sulzfeld, Germany). Adult, test-naïve, female Lewis rats (nulliparous and nonpregnant, aged 8-10 weeks, weighing 18-24 g) were purchased from Charles River Laboratories (Willimantic, CT). Rat OVA and passive anaphylaxis animal experimentation was conducted in accordance with German national guidelines and legal regulations and was approved by the Regierungspräsidium Tübingen Ethical Committee in Germany (permit number 13-025).
Animals were housed under conventional and certified laboratory conditions with a regular 12-hour dark/light cycle at ambient temperature of 22°C 6 2°C and a relative air humidity of 60% 6 15%, and they were kept in rooms maintained at constant temperature (22°C 6 2°C) and humidity (60% 6 15%) under a 12-hour light/dark cycle. The animals were housed in groups of two in isolated ventilated cages and were allowed free access to water and standard food. All efforts were made to minimize suffering. Animals were acclimated for at least 2 weeks before use. Animals were constantly monitored during induction and maintenance of anesthesia, and the level of narcotic was adjusted to maintain optimal depth of anesthesia.
Compound Preparation. BI 1002494 was synthesized as described in patent WO2011092128 as example 35. For in vitro assays, BI 1002494 was dissolved in dimethylsulfoxide (DMSO) and serial dilutions were prepared in DMSO prior to final dilution in assay SYK Inhibitor with Differential Cellular Pharmacology buffer. The final DMSO concentration was 1% in the kinase assays and 0.1% in the cellular assays. For animal experiments, BI 1002494 was dissolved in 0.5% hydroxyethylcellulose containing 0.01% Tween 20 and was applied by oral gavage.
SYK Enzyme Kinase Domain ATP Detection Assay. The catalytic activity of SYK was measured utilizing Kinase-Glo ATP detection reagent (Promega, Madison, WI), which quantifies residual ATP remaining in solution after the kinase reaction. The assay was performed in a 384-well OptiPlate (PerkinElmer, Waltham, MA) containing 4 nM GST (Glutathione S-transferase)-Syk kinase domain, 0.15 mM ATP, and 100 mg/ml poly(glutamic acid/tyrosine 4:1) [poly(EY) 4:1] in assay buffer consisting of 25 mM HEPES, pH 7.5, 25 mM MgCl 2 , 5 mM MnCl 2 , 50 mM KCl, 0.01% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid, 100 mM Na 3 VO 4 , and 1% DMSO. The buffer additionally contained either 0.2% or 1% human serum albumin. Test compound was preincubated with kinase for 15 minutes at room temperature before starting the reaction with the substrates. Positive control wells contained no test compound, and negative control wells contained no kinase or test compound. The kinase reaction mixture (15 ml total volume) was incubated for 60 minutes at room temperature, followed by the addition of 10 ml Kinase-Glo reagent. After 15 minutes of incubation at room temperature, the relative light unit signal was measured on an Envision reader (Agilent Technologies, Santa Clara, CA).
Details of the full-length SYK assays can be found in the Supplemental Methods.
Human and Rat Basophil Assays. Human whole blood collected into heparin blood collection tubes was obtained from healthy volunteers who had previously given their informed consent. All samples were anonymized prior to use. Two-hundred microliters of heparinized whole blood was aliquoted in a 48-well plate with 10 ml BI 1002494 and incubated at 37°C for 30 minutes. Forty microliters of hJL3 (stimulation buffer) was added, mixed, and incubated at 37°C in a water bath for 10 minutes. Two-hundred microliters of 60 ng/ml dinitroprusside (DNP)/bovine serum albumin (BSA) was added, mixed, and incubated at 37°C for 20 minutes. The reaction was stopped with the addition of 2 ml phospho-Fix solution (prediluted 1:5 in water and prewarmed to 37°C) and incubated at 37°C in a water bath for 10 minutes. Cells were immunostained with mouse anti-human IgE-PE antibody and mouse anti-human CD63-fluorescein isothiocyanate.
IgE/CD63
1 cells were identified as basophils. Twenty-five microliters of anti-DNP IgE monoclonal antibody Spe7 was added to 8 Â 10 5 cells/ml rat basophil cell line RBL-2HS and incubated for 30 minutes. Cells were washed once with Tyrode's buffer and 10 ml BI 1002494 was added and incubated for an additional 30 minutes in the presence of 25% rat serum. Five microliters of DNP-BSA (100 ng/ml final concentration) was added and incubated for 60 minutes. Twenty-five microliters of substrate (2.4 mM 4-metylumbelliferyl-2-acetamide-2-deoxy-b-D-glucopyranoside) was added and incubated for 45 minutes. Fluorescence intensity of the hydrolyzed substrate was measured in a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA) using 350-nm and 460-nm excitation and emission filters, respectively.
B-Cell CD69 Assay. Human whole blood collected into heparin blood collection tubes was obtained from healthy volunteers who had previously given their informed consent. All samples were anonymized prior to use. Heparinized whole blood was mixed gently and 45 ml was aliquoted on the bottom of a 96-well plate. Five microliters per well of BI 1002494 was added and preincubated for 30 minutes at 37°C in a water bath. Then 12.5 mg/ml goat anti-human IgD was added and the plate was incubated for 4 hours in 37°C in a water bath. Cells were stained with mouse anti-human CD19-fluorescein isothiocyanate and mouse anti-human CD69-phycoerythrin. CD19
1 B cells were identified by flow cytometry and the percentage of surface expression of CD69 was measured.
Rat Precision-Cut Lung Slices. To understand whether the cellular potencies of BI 1002494 translated into more functional readouts, the ex vivo PCLS platform was used to measure bronchoconstriction. Preparation of PCLSs and subsequent experiments were closely performed as described previously (Wohlsen et al., 2001) . PCLSs were prepared from rat lungs. Animals were euthanized with an intraperitoneal overdose of pentobarbital-Na (Merial GmbH, Hallbergmoos, Germany). Extraction of lung tissue was performed directly postmortem to conserve vitality of the tissue. Lung lobes were cannulated and filled with prewarmed 1.5% low-melting agarose/ medium solution and cooled on ice. Tissue cores of 8-mm caliber were prepared and cut into approximately 300-mm-thick slices using a microtome (Krumdieck tissue slicer; Alabama Research and Development, Munford, AL; or Vibratome OTS-5000; Science Services GmbH, Munich, Germany) in Earle's balanced salt solution. Sections were incubated overnight with 1% serum of OVA-sensitized rats. Reference tissue was incubated with 1% serum of nonsensitized rats. Single tissue sections were placed in cavities of petri dishes and fixed by a nylon thread attached by a wire to avoid movement during measurement. Airways of PCLSs were imaged and digitized using an inverted microscope and a digital video camera. Camera control and image analysis were achieved by Axiovision software (Carl Zeiss, Jena, Germany). The airway area before the addition of allergen was defined as 100%. Bronchoconstriction was expressed as the percentage of the initial airway area. Only slices with airways free of agarose, with beating cilia, and with an intact smooth muscle layer were used. Acute allergic airway constriction was induced by the addition of 0.1% OVA. Images of bronchoconstriction were taken by video microscopy. Images were recorded every 15 seconds for a 10-minute period. The experiment was conducted after preincubation with BI 1002494 for 30 minutes at 37°C. Preincubation with serum of nonallergic rats was used as a reference curve. Each measurement was performed with lung tissue from three rats.
Rat Pulmonary Passive Anaphylaxis Model. Brown Norway rats were briefly anesthetized with isoflurane [3% to 4% (v/v)] and 200 ml monoclonal anti-DNP IgE antibody [50 mg/ml in phosphatebuffered saline (PBS)] was administered intratracheally. Each animal received an additional 10 ml antibody (1 mg/ml in PBS) intradermally into the right ear. Twenty-four hours later, animals were briefly anesthetized and 1 mg DNP-BSA diluted in 0.9% saline with 1% Evans blue was injected into the tail vein. BI 1002494 was dosed orally 1 hour before challenge and the rats were euthanized by an intraperitoneal injection of pentobarbital (160 mg/kg narcoren), 30 minutes after the DNP-BSA challenge. Airway compliance was measured using the SCIREQ flexiVent (Emka Technologies, Paris, France). Under terminal anesthesia, blood samples were drawn from the retro-orbital plexus into EDTA for analysis of BI 1002494 concentrations. Animals were euthanized and the respiratory tract, including the larynx, trachea, and lung, was removed. Ear tissue biopsies were taken from both ears using a tissue punch (8-mm diameter). Evans blue was extracted by incubating the trachea together with the bronchial tissue in 2.5 ml formamide and the ear tissue in 0.5 ml formamide at 65°C overnight with gentle agitation (450 rpm). Twenty-four hours later, the absorbance in the supernatant was measured at 620 nm using a spectrophotometer.
Rat OVA Model. Fifteen milligrams of OVA was dissolved in 10 ml PBS prior to being mixed with 5 ml alum. On days 0, 1, and 2, brown Norway rats were immunized intraperitoneally with approximately 1 ml/kg with PBS/alum (negative controls) or OVA/alum (positive controls and treatment groups). Animals were returned to their home cage to recover. On days 5 and 6, rats were challenged with inhaled saline [negative controls] or OVA [1% (w/v); positive controls and treatment groups] at a flow rate of 10 l/min for 20 minutes. Animals remained in the inhalation chambers for an additional 1 minute, after which the air was evacuated (60 l/min) and the animals were returned to their home cage. BI001002494 was dosed orally 1 hour before andRat Collagen-Induced Arthritis Model. In the rat collageninduced arthritis (CIA) model, Lewis rats received two divided intradermal injections totaling 400 ml collagen emulsion (containing 400 mg type II collagen emulsified with Freund's incomplete adjuvant) at the base of the tail. Seven days later, rats received a booster injection of 100 ml collagen emulsion (containing 100 mg type II collagen emulsified with Freund's incomplete adjuvant) at the base of the tail. Three days after the booster injection, rats with visible arthritis symptoms were randomly enrolled into treatment groups. Hind paw volume was assessed daily.
Results
Kinase and Cellular Potencies of BI 1002494. The structure of BI 1002494 is shown in Fig. 1 . To understand the potency of BI 1002494 against SYK, a number of kinase assays were employed (or developed) using either the kinase domain only (i.e., constitutively active) or the full-length kinase (i.e., not constitutively fully activated), together with a number of different generic and/or physiologically relevant substrates. The potency of BI 1002494 in the SYK kinase domain activity assay in ATP detection format with poly(GluTyr)(4:1) as a substrate was 1 nM in the presence of both 0.2% and 1% human serum albumin (Table 1 ). In the full-length SYK competition binding assay and full-length SYK catalytic activity assay using the KinEASE-TK peptide as a substrate, the potency was approximately 30 nM. This potency was 220 nM in the full-length SYK catalytic activity assay when B-cell linker (BLNK) protein was used as a substrate.
The potency of BI 1002494 was tested in a number of different cellular assays to understand the effect and potency of the SYK inhibitor across different cell types that are implicated in different inflammatory/autoimmune diseases. Where possible, assays were performed in whole blood or in the presence of protein for better comparison of intracellular potencies. The IC 50 of BI 1002494 for Fc«R1-mediated histamine release in human monocyte-derived mast cells was 7 nM in the presence of 0.1% albumin (Table 2) , which translates into an IC 50 value of 159 nM when adjusted for the proportion of compound bound to protein in the assay (93.2%). This agreed well with the potency of 115 nM for Fc«R1-mediated CD63 surface expression on peripheral basophils in human whole blood. The IC 50 in the rat basophil cell line RBL-2H3 was 323 nM in the presence of 25% rat serum, approximately 3-fold less potent than that for human basophils.
BI 1002494 also inhibited the activation of B cells (Table 2) . However, the potency of BI 1002494 in blocking CD69 expression after anti-IgD (BCR) stimulation of peripheral B cells was 7-fold lower than in basophils/mast cells, with an IC 50 value of 810 nM (Fig. 2 ). An analysis of 171 additional compounds that included examples from a diverse set of compounds revealed only 21 compounds (12%) with better potency on CD69 versus CD63 expression (Fig. 3A) ; across the compound panel, the average difference between CD63 and CD69 IC 50 was 6.9-fold (Fig. 3B) , suggesting that the finding with BI 1002494 indeed represents a biologic difference of SYK inhibition in mast cells and B cells.
Unlike the cross-species potency differences we observed in the basophils/mast cells, the mouse B-cell CD69 IC 50 was 933 nM, which agreed well with the human B-cell potency ( Fig. 2 ; Table 2 ). Because of technical limitations, it was not possible to generate a B-cell CD69 potency in rat B cells.
Physicochemical Properties and Selectivity of BI 1002494. Plasma protein binding varied between species, with values ranging from 93.2% to 95.6% (Table 3) . Hepatocyte stability was estimated between 36% and 68% of human liver blood flow, depending on the species, resulting in a sustained plasma exposure above the in vitro IC 50 values from the twicedaily dosing profile in rat (Fig. 2) . Cytotoxicity, human ethera-go-go-related gene potassium channel (hERG) inhibition, good cell permeability, and aqueous solubility were all within the acceptable range for an in vivo tool compound (Table 3) .
In the LanthaScreen, Z9-Lyte, and Adapta kinase profiling screens (Invitrogen/Thermo Fisher Scientific, Carlsbad, CA), BI 1002494 inhibited only 23 of the 283 available kinases greater than 50% at 1 mM test concentration (Supplemental Table 1 ). Furthermore, only three receptors were bound more than 50% at 10 mM in the ExpresSProfile screen (Eurofins Cerep SA, Celle L'Evescault, France) (Supplemental Table 2 ).
Potency Translation of BI 1002494 to Ex Vivo and In Vivo Models. Finally, we sought to determine whether the different potencies generated in the kinase and cellular assays translated into differences in efficacy in the ex vivo PCLS platform and across a range of in vivo models.
Bronchoconstriction of passively sensitized and challenged rat PCLSs was inhibited by BI 1002494 with an IC 50 value of 70 nM (Fig. 4) . These findings were obtained in the presence of 1% serum. The shift in potency in the RBL-2H3 assay from 1% serum to 25% serum was approximately 6-fold (data not shown). Taking into account this serum shift, this IC 50 value agrees well with the rat basophil IC 50 of 323 nM. Airway resistance (Fig. 4) was also measured in a pulmonary passive sensitization and challenge rat model with IC 50 values of 735 nM, which also agrees well with both basophil and PCLS potencies.
BI 1002494 dose-dependently inhibited OVA-induced bronchioalveolar lavage eosinophils in brown Norway rats, with twice-daily 30 mg/kg providing 91% inhibition (Fig. 5A ). An exposure simulation of twice-daily 30 mg/kg in brown Norway rats resulted in a trough plasma concentration of (Fig. 6) , which provided 24-hour coverage of the rat basophil IC 50 adjusted for plasma protein binding (323 nM). BI 1002494 was tested in the Lewis CIA rat (Fig. 5B) . A dose of 10 mg/kg provided full efficacy; however, despite the relatively lower dose, an exposure simulation of this dose in Lewis rats resulted in a higher trough plasma concentration of 1400 nM (Fig. 6) , a 40% increase in the plasma concentration area under the curve (data not shown), and 24-hour coverage of the human/mouse B-cell IC 50 adjusted for plasma protein binding (810/938 nM respectively), which was significantly higher than the rat basophil IC 50 . Unfortunately, it was not technically possible to generate a rat B-cell IC 50 ; nevertheless, there was good agreement between potency values in both humans and mice (Table 2) .
Discussion
We describe here a novel, potent, and selective SYK inhibitor with a good rodent PK profile, low cytotoxicity, hERG inhibition, and good cell permeability. When designing, interpreting, and reporting preclinical studies, it is important to fully understand the cellular potencies, selectivity, and PK of the tool compound selected, as recently stated by a crossacademic/pharmaceutical working group (Arrowsmith et al., 2015) . BI 1002494 fulfills these criteria; it is more selective than fostamatinib (Braselmann et al., 2006) , cerdulatinib (Coffey et al., 2014) , R343 , and LAS189386 (Ramis et al., 2015) and has better rodent PK compared with BAY 61-3606 (Bhagwat, 2009 ). The selectivity profile of BI 1002494 is broadly similar to that of PRT062607 (Coffey et al., 2012) ; however, unlike PRT062607, BI 1002494 demonstrates 10-fold greater selectivity over p21-activated kinase PAK4 (PRT062607 PAK4 IC 50 5 24 nM; BI 1002494 PAK4 IC 50 5 189 nM), which may inhibit cell proliferation in tissues with high cellular turnover (e.g., bone marrow). The recently published data on entospletinib (GS-9973) suggest that the selectivity profile is similar to that of BI 1002494 but is 3-to 10-fold less potent on SYK (IC 50 5 7.7 nM versus 0.8 nM) and in the basophil CD63 assay (IC 50 5 387 nM versus 115 nM) (Currie et al., 2014) .
We observed that BI 1002494 was more potent in human basophils and mast cells, as measured by CD63 surface expression and histamine release, respectively, compared with B-cell activation, as measured by CD69 expression. We initially hypothesized that this finding was an artifact of variability in the assays. However, an analysis of a panel of 171 SYK inhibitors (which included examples from a diverse set of compounds) revealed 147 compounds (86%) with better potency in mast cells (basophils) versus B cells. Furthermore, the average difference between the potencies was 6.9-fold, which agrees very well with the CD63/CD69 ratio of 7.0 for BI 1002494, suggesting that this discrepancy between basophil and B-cell potencies is real. The number of repetitions for CD63 (n 5 317) and CD69 (n 5 21) also suggests that these differences are not a result of assay variability. Both fostamatinib (Braselmann et al., 2006) and LAS189386 (Ramis et al., 2015) are reported to have potency values for B cells equal to or even better than those for basophils, which may be a consequence of their lower selectivity profile.
The potency of BI 1002494 was initially determined using a kinase domain-only fragment of SYK and the poly(EY) 4:1 peptide substrate, a universal substrate for protein tyrosine kinases. However, this potency was lowered when the kinase domain was replaced with the full-length kinase and the potency determined by competitive binding with an ATPcompetitive kinase inhibitor scaffold (kinase tracer 236). The recently published crystal structure of the full-length SYK kinase, combined with some elegant mutation and binding studies, reveals that contrary to the kinase domain (in which the ATP binding site is active), the full-length kinase ATP binding site exists in an autoinhibited conformation (Grädler et al., 2013 ). An activation loop that enables the phosphorylated immunoreceptor tyrosine-based activation motif domain to bind to the SH2 domain facilitates activation of the site. This may explain the decrease in potency of BI 1002494 from an assay containing the "active" ATP binding site kinase domain to 50 , nM 159 n/a n/a n/a n/a HSA, human serum albumin; n/a, not applicable; PPB, plasma protein binding.
an assay containing the full-length "autoinhibited" ATP binding site. The activation loop contains at least two phosphorylation sites: Tyr348 and Tyr352. It is not known in a cellular setting whether the full-length SYK exists in the autoinhibited, active, or partially active conformation. We can assume that the potency is probably lower in cells compared with purified kinase protein because of the requirement for the compound to partition across the plasma membrane. Given that the human mast cell IC 50 for BI 1002494 in the presence of only low levels of albumin was 7 nM, which is closer to the potency in the kinase domain (activated kinase form) assay (IC 50 5 1 nM) compared with that of the full-length kinase assay (IC 50 5 34 nM), this suggests that the full-length kinase may be fully or at least partially activated in the cell.
Next we asked what mechanism(s) could account for the discrepancy between basophil/mast cell and B-cell potency of BI 1002494. In the full-length kinase assay, the potency of BI 1002494 was similar in assays measuring displacement of a tracer (IC 50 5 34 nM) and phosphorylation of a tyrosine kinase peptide substrate (homogeneous time resolved fluorescence KinEASE-TK substrate, 36 nM). However, there was a marked decrease (IC 50 5 220 nM) when this substrate was exchanged for the physiologic substrate for SYK in B cells, BLNK (Ishiai et al., 1999) . Although it is difficult to draw firm conclusions without the comparison with the physiologic substrate for SYK in basophils/mast cells, LAT (Linker of activated T-cells), it provides a plausible explanation for the differences between the basophil/mast cell and B-cell potency. Consistent with these findings, Gilead also reported that GS-9973 displays an offset in potency between SYK (IC 50 5 7.7 nM) and SYK with BLNK as the substrate (IC 50 5 26 nM) (Currie et al., 2014) . .10 Cytotoxicity (U937 cells), mM 2 5 P-glycoprotein inhibition, mM 6 Aqueous solubility (HCl salt), mg/ml pH 1 0.9 pH 3 0.9 pH 5 0.9 pH 7.4 0.5 pKa 3 . 2 logP 2.5 %QH, percentage liver blood flow. Fig. 4 . Efficacy of BI 1002494 in rat basophils, rat PCLSs, and rat pulmonary bronchoconstriction. Translation of BI 1002494 potency between rat basophils (solid black squares), bronchoconstriction in rat PCLSs (open black circles), and airway resistance in a rat model of pulmonary passive sensitization and challenge (solid gray circles). Rat RBL-2HS cells were preincubated with BI 1002494 in the absence of serum, and the Fc«R1 was loaded with anti-DNP IgE and stimulated with DNP. Degranulation was measured by release of b-hexosamidase into the medium (n = 4). PCLSs were preincubated with BI 1002494 and passively sensitized with serum from OVA-sensitized rats. Sections were stimulated with OVA and bronchoconstriction was measured by video microscopy. Experiments were performed in duplicate with material from three rats. Finally, pulmonary mast cells in rats were passively sensitized by intratracheal administration of anti-DNP IgE. Twenty-four hours later, rats were challenged with DNP and airway resistance was measured via a flexiVent. Each data point represents four rats. Data are adjusted for the protein unbound fraction of compound. 
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The apparent lower potency in human B cells may have a consequence for selection of a human dose, depending on the indication in which the SYK inhibitor is positioned, which was supported by the higher exposures required in the rat CIA model for full efficacy. If the B cell is the desired target in diseases such as rheumatoid arthritis (fostamatinib, PRT062607, HMPL-523, GS-9876) or B-cell lymphoma (PRT062070, GS-9973, TAK-659 [diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate]), then a dose resulting in a higher exposure that covers the potency in the B-cell CD69 assay is likely required. In this scenario, estimating human efficacious exposures is somewhat easier when there is no observable species potency shift between human and mouse B cells. Similarly, there was no difference between mouse basophil and mouse B-cell potencies for BI 1002494 (data not shown).
However, if the basophil/mast cell axis is targeted in diseases such as asthma (R-343, LAS189386), then a lower dose that provides exposure covering the potency in these cell types may be sufficient. Whether coverage of B-cell activation is required for better efficacy in asthma is an open question. However, there is no direct evidence that B-cell depletion and/ or loss of function would be beneficial in asthma, and loss of regulatory B cells exacerbates allergic airway inflammation in mice (Amu et al., 2010) . Furthermore, compromising B-cell function may even be deleterious in patients with asthma who rely on vaccine protection from respiratory viruses (e.g., influenza) to prevent exacerbation (Wells et al., 2015) , and there is evidence that B-cell depletion impairs response to the influenza vaccine (Bedognetti et al., 2011) . However, fostamatinib demonstrated no effect on IgG or IgM responses after keyhole limpet hemocyanin challenge, nor did it affect bacterial or viral clearance in listeria, streptococcal, or influenza host-resistance mouse models (Zhu et al., 2007) , suggesting that B-cell responses may not be impaired, even at higher exposures that cover the CD69 activation assay. The choice of indicationrelevant cellular assay therefore has an important influence on the estimated human efficacious exposure.
Acute asthmatic attacks in patients, in the in vivo rat anaphylaxis model, and, to a lesser extent, in the OVA model rely on mast cell degranulation. However, assessment of target engagement by a pharmacological intervention in tissue cells is difficult. It is therefore common to use a peripheral cell as a surrogate; in this case (and in the literature; Braselmann et al., 2006) , the basophil was selected. Our work increases the confidence that the potency of an SYK inhibitor in the peripheral basophil is a good marker for potency in the tissue mast cell. We compared the potency of BI 1002494 in the in vitro rat basophil degranulation assay (IC 50 5 323 nM), ex vivo bronchoconstriction in rat PCLSs (IC 50 5 70 nM, which was generated in the presence of 1% serum and would result in an IC 50 value of approximately On days 5 and 6, rats were challenged with inhaled OVA [1% (w/v)]. BI 1002494 was dosed orally 1 hour before and 8 hours after OVA challenge on days 5 and 6. On day 7, rats were euthanized, the lungs were lavaged, and the number of eosinophils was counted. Each data point is the mean 6 S.E.M. from eight rats. (B) Lewis rats received two intradermal injections of collagen emulsion in Freund's incomplete adjuvant at the base of the tail. Seven days later, rats received a booster injection of collagen in Freund's incomplete adjuvant. Three days after the booster injection, rats with visible arthritis symptoms were randomly enrolled into treatment groups of vehicle (solid black circles), 3 mg/kg BI 1002494 (open black circles), 10 mg/kg BI 1002494 (solid black squares), or 30 mg/kg BI 1002494 (open black squares) and treated twice daily for 14 days. Hind paw volume was assessed daily. Each data point is the mean 6 S.E.M. from eight rats. ***P,0.005; ****P,0.001. Fig. 6 . Simulated plasma exposure of BI 1002494 in brown Norway and Lewis rats after twice-daily oral dosing. Plasma exposures for twice-daily dosing (at 0 hours and 8 hours) were simulated for brown Norway rats (black squares) and Lewis rats (gray circles) from 24-hour plasma exposure profiles after a single 10-mg/kg oral administration in three rats. Trough plasma levels of 1400 nM (Lewis rat, 10 mg/kg,) and 340 nM (brown Norway rat, 30 mg/kg) were calculated. 400 nM if adjusted for the approximate 6-fold serum shift observed in the RBL-2H3 assay), and in vivo reversal of airway resistance in a rat pulmonary anaphylaxis model (IC 50 5 735 nM). The good agreement between potencies generated in the cellular assay (as a surrogate for the peripheral basophil) and the tissue mast cells both in tissue preparations and in an in vivo model suggest that in this case, the basophil is a reasonable surrogate for estimation of compound potency in tissue mast cells.
Although the fully efficacious dose in the rat CIA model was lower than that required for the rat OVA model, the plasma exposures differed considerably between rat strains. Consequently, higher exposures were required for efficacy in the CIA model compared with the OVA model. It is therefore important to consider both dose and exposure when assessing the potency of a tool compound in vivo.
In summary, BI 1002494 is a novel, potent, and selective SYK inhibitor with a good rodent PK profile, low cytotoxicity, and hERG and P-glycoprotein inhibition. Potency in human mast cells and basophils was consistently better than in human B cells, which is perhaps explained by a lower potency when the physiologic B-cell substrate BLNK was substituted in the kinase assay. A potency shift was observed between humans and rats, but these potencies translated well between in vitro and ex vivo test systems and into efficacious exposures in the respective species in vivo models. Taken together, these data provide a robust platform from which to estimate human efficacious exposures according to the relevant cell type for the indication intended to be treated. Journal of Pharmacology and Experimental Therapeutics (JPET)
METHODS

SYK enzyme -full length LanthaScreen competition binding assay
LanthaScreen competition binding assay (Life Technologies) of GST-Syk was based on the binding and displacement of Alexa Fluor647-labeled kinase tracer to the ATP-binding site of the kinase with TR-FRET detection using a europium-labeled anti-GST antibody. The assay was performed in 384-well, low volume NBS black plates (Corning) containing 2 nM GST-Syk full-length (Life Technologies), 1 nM kinase Tracer236 and 2 nM Eu3+-anti-GST antibody in assay buffer consisting of 50 mM HEPES, pH 7.5, 10 mM MgCl 2 , and 0.01% Brij 35, 0.01% BSA, 1 mM DTT, and 1% DMSO. Positive control wells contained no test compound, and negative control wells contained no kinase or test compound. The kinase reaction mixture (15 µL total volume) was incubated for 60 min at room temperature, and then the TR-FRET signal was read on a VIEWLUX using 340 nm excitation filter and 671 nm emission filter.
SYK enzyme full length HTRF assay usingTK peptide substrate
The catalytic activity of full-length Syk was measured using HTRF KinEASE-TK assay (CisBio) which uses a unique biotinylated peptide substrate (TK-peptide) containing a single tyrosine phosphorylation site, which when phosphorylated is recognized by a monoclonal anti-phosphotyrosine antibody labeled with Eu 3+ cryptate. The assay was performed in 384-well Optiplate containing 3 nM GST-Syk full-length (Life Technologies), 500 nM biotin-TK pepride and 5 µM ATP in assay buffer consisting of 250 mM HEPES, pH 7.0, 0.05% BSA, 0.1% NaN 3 , 10 mM MgCl 2 , 100 µM Na 3 VO 4 , 1 mM DTT and 1% DMSO. Test compound was pre-incubated with kinase for 15 min at room temperature before starting the reaction with the substrates. Positive control wells contained no test compound, and negative control wells contained no kinase or test compound. The kinase reaction mixture (10 µL total volume) was incubated for 60 min at 37C followed by addition of 10 µL detection mix containing a 1:1 mixture of TK antibody Cryptate and 250 nM Streptavidin XL-665. After additional 60 minutes of incubation at room temperature, TR-FRET signal was read on an EnVision (Excitation: 340 nm; Emissions:615 and 665 nm).
SYK enzyme full length HTRF assay using BLNK protein substrate
The catalytic activity of full-length SYK was measured utilizing His-tagged BLNK protein substrate (GenWay) with TR-FRET detection of phosphorylated BLNK with Eu 3+ -labeled anti-His antibody (Life Technologies) and custom d2-labeled anti-phospho BLNK (Try84) antibody (CisBio). The assay was performed in 384-well Optiplate containing 3 nM GST-Syk full-length (Life Technologies), 25 nM His- 
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